α-干扰素联合拉米夫定治疗慢性乙型肝炎临床疗效评价

Evaluation of Clinical Curative Effect of α-Interferon and Lamivudine on the Treatment of Chronic Type B Hepatitis

目的:对比观察单用拉米夫定与α-干扰素联合治疗慢性乙型肝炎的疗效和安全性。方法:拉米夫定组30例,给予拉米夫定100mg/日,服用12个月;干扰素组28例,给予α-干扰素5MU疗程12个月;联合组48例,给予拉米夫定100mg/日,两周后联合α-干扰素5MU肌肉注射,每日1次,疗程4周后,改为隔日1次,继续服用拉米夫定治疗12个月。观察1个月、3个月、6个月、12个月治疗结果。结果:联合组的疗效显著高于其他组(P<0.05),12个月时3组ALT/AST复常率分别为80.8%、70.5%和76.6%(P>0.05)。结论:拉米夫定联合干扰素治疗慢性乙型肝炎,安全性、耐受性良好,联合组治疗1年后HbeAg血清转换率明显高于单用拉米夫定和干扰素组。

OBJECTIVE： To compare the efficacy and the safety of singly using lamivudine and combined use of Lamivudine and α- interferon （IF）. METHODS： 30 cases in lamivudine group were given lamivudine 100 mg/d for 12 months; 28 cases in IF group were given α - IF 5 MU by IM injection, once every 2 days for continuously 6 months, then changing to 3 times every week. To increase response rate of IF, the dosage could be increased to 10 MU, course of treatment lasted 12 months; 48 cases in combined group were given lamivudine 100 mg/d for 2 weeks, then combined use of α - IF 5 MU by IM injection, once per day for 4 weeks, then changing to once every 2 days, continuously using lamivudine for 12 months. Treatment results of 1 month, 3 months, 6 months and 12 months were respectively observed. RESULTS： Curative effect in combined group was obviously higher than that in other groups （ P 〈 0.05）. The rate of returning to normal in ALT/AST in 3 groups in 12 months was 80.8%, 70.5% and 76.6% respectively （P 〉 0.05）. CONCLUSION： Combined use of lamivudine and IF for the treatment of chronic type B hepatitis has obtained good safety and tolerance . After one year＇s treatment , frequence of seroconversion of HBeAg in combined group is significantly higher than that in the groups which singly using lamivudine or IF.